Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Intellipharmaceutics International Inc. (IPCIF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.07690.0000 (0.00%)
At close: 02:40PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0769
Open0.0710
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0769 - 0.0769
52 Week Range0.0600 - 0.1600
Volume5,930
Avg. Volume4,031
Market Cap2.545M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-0.1080
Earnings DateOct 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Intellipharmaceutics Announces Third Quarter 2022 Results

    - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022.

  • ACCESSWIRE

    Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets

    Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. ("Taro"), by which the Company has granted Taro an exclusive license to

  • ACCESSWIRE

    Intellipharmaceutics Announces Second Quarter 2022 Results

    Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Advertisement
Advertisement